Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

After 12 months off-treatment, a second romosozumab course again led to rapid and large BMD gains. Following denosumab, BMD gains with romosozumab were smaller than with initial treatment. No new safety findings were observed during the second course.